Compare Domino's Pizza, Inc. (DPZ) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Domino's Pizza, Inc. trades at $295.91 (market cap $9.73B), while GE HealthCare Technologies Inc. Common Stock trades at $69.47 (market cap $30.93B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 3.2× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| DPZ | GEHC | |
|---|---|---|
Market Cap | $9.73B | $30.93B |
Volume | 1,426,037 | 5,033,451 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $88.16 |
52-Week Low | $282.89 | $59.48 |
Typical Hold Time | 106 Days | — |
Enterprise Value | $14.63B | $39.39B |
Dividend Yield | 2.69% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $296.10, down 4.76% with recent earnings showing mixed results including a Q3 2026 beat. The stock maintains strong profitability with 12.03% net margin and trades at reasonable valuations (P/E 16.3, P/S 1.96). Technical indicators show a bullish overall signal despite near-term bearish pressure, with key support at $297. Recent news highlights dividend stability amid high debt levels and store closures in certain markets.
DPZ presents a compelling value opportunity with analyst consensus target of $361.44 (22% upside), though significant debt load and recent earnings misses warrant caution. The company's consistent revenue growth and strong cash flow generation support dividend sustainability, but competitive pressures and execution risks remain key watchpoints for investors.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
